Literature DB >> 15500565

Pharmacokinetics of florfenicol in North American elk (Cervus elaphus).

J Alcorn1, P Dowling, M Woodbury, R Killeen.   

Abstract

Florfenicol pharmacokinetics after administration of a single subcutaneous (s.c.) dose of 40 mg/kg of body weight in adult elk (Cervus elaphus) was investigated. Serum florfenicol concentrations were determined by a sensitive high-performance liquid chromatographic method with limit of quantification of 0.03 microg/mL. Florfenicol pharmacokinetic parameters in elk were estimated using a noncompartmental approach. After a single s.c. injection, florfenicol concentrations remained above 1 microg/mL for approximately 36 h and above 0.5 microg/mL for approximately 72 h. Following s.c. injection, florfenicol was absorbed rapidly with a mean maximum concentration (C(max)) of 3.7 microg/mL achieved at 4.2 h (T(max)). The C(max) value in elk is similar to values reported in cattle at the same dose, suggesting that the 40 mg/kg s.c. dose achieves therapeutic concentrations in elk. A mean elimination half-life (t(1/2)) of 44 h is shorter than that reported in cattle. The more rapid elimination half-life in elk suggests that elk may require a multiple dose regimen for therapeutic success with s.c. Nuflor. We recommend s.c. Nuflor be administered subcutaneously to elk every 24 h at a dose level of 40 mg/kg.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15500565     DOI: 10.1111/j.1365-2885.2004.00594.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  2 in total

1.  Florfenicol pharmacokinetics in healthy adult alpacas after subcutaneous and intramuscular injection.

Authors:  K Holmes; D Bedenice; M G Papich
Journal:  J Vet Pharmacol Ther       Date:  2011-07-08       Impact factor: 1.786

2.  Optimization of florfenicol dose against Piscirickettsia salmonis in Salmo salar through PK/PD studies.

Authors:  Betty San Martín; Marcela Fresno; Javiera Cornejo; Marcos Godoy; Rolando Ibarra; Roberto Vidal; Marcelo Araneda; Arturo Anadón; Lisette Lapierre
Journal:  PLoS One       Date:  2019-05-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.